
ElsaLys Biotech spins out of Transgene, raises €2.1mm in Series A round
Executive Summary
Immunotherapeutics company Transgene SA (majority owned by Institut Merieux) has spun out ElsaLys Biotech, and participated in the monoclonal antibody firm’s €2.1mm ($2.7mm) Series A round, which also included Sofimac Partners.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice